Penn Medicine Lancaster |

CAR-T cell immunotherapy is a breakthrough treatment developed in Pennsylvania.

YORK, Pa. — Penn Medicine Lancaster General Health’s Ann B. Barshinger Cancer Institute now offers advanced cancer treatment CAR-T cell immunotherapy, a breakthrough immunotherapy developed at Penn Medicine in Philadelphia.

CAR T (Chimeric Antigen Receptor T-cell) is a form of cancer therapy that uses specially modified endogenous immune cells from the patient. T cells, a type of white blood cell, are taken from the patient and reprogrammed to find and attack cancer cells when reinfused into the bloodstream.

Penn Medicine is a global leader in immunotherapy research advancing the safety and efficacy of CAR T. CAR T was the first gene therapy to be approved by the Food and Drug Administration (FDA) and ushered in a new era of cancer treatment options.

CAR-T cell therapy is used to treat patients with certain types of aggressive blood cancers that have not responded to one or more therapies, such as B. Large B-cell lymphoma, the most common form of non-Hodgkin’s lymphoma.

FOX43 spoke to the medical director of the Ann B. Barshinger Cancer Institute to find out why this new treatment could change the way cancer is treated in the future.

“We have a new option that, given just once, has the potential to heal someone, save their life, and make them live longer,” said Dr. Randall Oyer. “We now find that the original patients, who were literally on their deathbeds from their advanced cancer, have been cured.” In fact, without additional treatment, the patients had not had their cancer recurrence in more than 10 years, which Dr. Oyer is nothing short of amazing.

The Ann B. Barshinger Cancer Institute in Lancaster offers CAR T-cell therapy for adult patients with diffuse large B-cell lymphoma (DLBCL).

For other adult diseases treatable with CAR-T, as well as for experimental CAR-T therapies, patients are being treated at Penn Medicine in Philadelphia.

Penn Medicine is also evaluating CAR-T therapy for other cancers and is enrolling eligible patients in clinical trials.

More information on CAR-T cell therapy can be found here.

Download the FOX43 app here. Penn Medicine Lancaster |

Alley Einstein is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button